Arena Pharmaceuticals Inc.
www.arenapharm.com
Latest From Arena Pharmaceuticals Inc.
Tech Transfer Roundup: Be Cool Therapeutics Sees Potential In Mimicking Hibernation
Biotech licenses drug composition patents from University of Alaska Fairbanks for study in several disease states. Gilead seeks long-acting HIV therapy or prevention with broadly neutralizing antibodies discovered by Rockefeller U.
10 Drug Launch Flops Of The Decade
The view from 2020: Scrip looks back over the last decade at the drug launches that defied expectations – for the worse.
Takeda's Entyvio Beats Humira In Head-To-Head Ulcerative Colitis Trial
Takeda’s gut-selective biologic vedolizumab pushes ahead of other biologics in the race to make its mark in ulcerative colitis, a therapeutic sector targeted by numerous new investigational therapies.
Can Vivus Get Away Without Outcomes Study Of Obesity Drug Qsymia?
Fixed-dose combination of phentermine and topiramate is FDA-approved for chronic, long-term use, but the average duration in the real world is only about 2.1 months, which is reassuring for Qsymia’s cardiovascular safety, according to a new retrospective claims study.
Company Information
- Industry
-
Biotechnology
- Drug Discovery Tools
- Pharmaceuticals
- Therapeutic Areas
- Cardiovascular
- Gastrointestinal
- Immune Disorders
- Metabolic Disorders
- Neurology, Nervous System
- Respiratory, Pulmonary
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Arena Pharmaceuticals Inc.
- Senior Management
-
Amit Munshi, Pres. & CEO
Kevin R Lind, EVP, CFO
Vince Aurentz, EVP, CBO
Preston Klassen, MD, EVP, R&D & CMO - Contact Info
-
Arena Pharmaceuticals Inc.
Phone: (858) 453-7200
6154 Nancy Ridge Dr.
San Diego, CA 92121
USA